A Novel Single Domain Antibody Targeting FliC Flagellin of Salmonella enterica for Effective Inhibition of Host Cell Invasion by Huen, Jennifer et al.
fmicb-10-02665 November 25, 2019 Time: 15:4 # 1
ORIGINAL RESEARCH




University of Teramo, Italy
Reviewed by:
Daniel Zabetakis,
United States Naval Research
Laboratory, United States
Chunlei Shi,
Shanghai Jiao Tong University, China
Kevin A. Henry,









†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Food Microbiology,
a section of the journal
Frontiers in Microbiology
Received: 22 February 2019
Accepted: 01 November 2019
Published: 26 November 2019
Citation:
Huen J, Yan Z, Iwashkiw J,
Dubey S, Gimenez MC, Ortiz ME,
Patel SV, Jones MD, Riazi A,
Terebiznik M, Babaei S and
Shahinas D (2019) A Novel Single
Domain Antibody Targeting FliC
Flagellin of Salmonella enterica
for Effective Inhibition of Host Cell
Invasion. Front. Microbiol. 10:2665.
doi: 10.3389/fmicb.2019.02665
A Novel Single Domain Antibody
Targeting FliC Flagellin of Salmonella
enterica for Effective Inhibition of
Host Cell Invasion
Jennifer Huen1,2,3†, Zhun Yan1†, Jeremy Iwashkiw1, Shraddha Dubey1,
Maria C. Gimenez2,3, Maria E. Ortiz2,3, Saumil V. Patel1, Michael D. Jones1, Ali Riazi1,
Mauricio Terebiznik2,3* , Saeid Babaei1* and Dea Shahinas1*
1 AbCelex Technologies Inc., Mississauga, ON, Canada, 2 Department of Biological Sciences, University of Toronto at
Scarborough, Toronto, ON, Canada, 3 Department of Cell and Systems Biology, University of Toronto at Scarborough,
Toronto, ON, Canada
The enteric pathogen, Salmonella enterica is a major cause of human gastroenteritis
globally and with increasing bacterial resistance to antibiotics, alternative solutions are
urgently needed. Single domain antibodies (sdAbs), the smallest antibody fragments
that retain antigen binding specificity and affinity, are derived from variable heavy-chain
only fragments (VHH) of camelid heavy-chain-only immunoglobulins. SdAbs typically
contain a single disulfide bond simplifying recombinant protein production in microbial
systems. These factors make sdAbs ideally suited for the development of effective anti-
bacterial therapeutics. To this end, we generated an anti-Salmonella VHH library from
which we screened for high affinity sdAbs. We present a novel sdAb (Abi-Se07) that
targets the Salmonella virulence factor, FliC, required for bacterial motility and invasion
of host cells. We demonstrate that Abi-Se07 bound FliC with a KD of 16.2 ± 0.1 nM.
In addition, Abi-Se07 exhibited cross-serovar binding to whole cells of S. enterica
serovar Typhimurium, Heidelberg, and Hadar. Abi-Se07 significantly inhibited bacterial
motility and significantly reduced S. enterica colonization in a more native environment of
chicken jejunum epithelium. Taken together, we have identified a novel anti-Salmonella
sdAb and discuss future efforts toward therapeutic development.
Keywords: single domain antibody, Salmonella enterica, pathogen, bacterial motility, bacterial invasion, binding
affinity
INTRODUCTION
The Gram-negative bacterium, Salmonella enterica is a common contaminant in the food industry
(Humphrey and Jørgensen, 2006; Crim et al., 2015). In chickens, S. enterica colonize the
gastrointestinal tract, with little to no disease (Doyle and Erickson, 2006; Hugas and Beloeil, 2014;
Mazengia et al., 2014; Wigley, 2014; Florez-Cuadrado et al., 2018). Consumption of bacteria-
contaminated food products can cause non-typhoidal salmonellosis, an acute gastrointestinal
illness in humans presenting with nausea, vomiting, diarrhea, and abdominal pain lasting 3–7 days
(Crum Cianflone, 2009). Worldwide, it is estimated that the prevalence of salmonellosis is
3.4 million cases with over 680,000 deaths annually (Ao et al., 2015; Balasubramanian et al.,
2018). With the large and growing market for broilers and the emergence of antibiotic resistant
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strains, alternative strategies to control S. enterica in livestock are
needed in order to reduce the zoonotic infections.
The field of antibody therapeutics has expanded significantly
in the past decade, with a record number of antibody
drugs (12) approved in 2018 (Kaplon and Reichert, 2018).
Technological advances have been integral in the identification
and development of several formats of antibody based biologics,
from full length antibodies that bind to tumor necrosis factor for
the treatment of inflammatory diseases (Humira R©, Salfeld et al.,
1998; Alizadeh et al., 2015; Frenzel et al., 2016) to engineered
fragments that neutralize neurotoxins produced by Clostridia
(Miethe et al., 2014; Frenzel et al., 2016; Wang et al., 2016). Single
domain antibodies (sdAbs) have become attractive molecules in
therapeutic research. SdAbs are derived from the camelid heavy
chain antibodies (HcAbs) where each antigen binding arm is
composed of a variable heavy-chain-only domain (VHH) with
three complementarity determining regions (CDRs) (reviewed
in Arbabi-Ghahroudi, 2017). SdAbs are the smallest unit of the
antibody (∼15 kDa) retaining binding specificity and affinity
to antigen (De Meyer et al., 2014; Arbabi-Ghahroudi, 2017).
The CDR3 of sdAbs is the most variable of all CDRs in both
amino acid content and length (Muyldermans et al., 1994; Vu
et al., 1997; Griffin et al., 2014). VHH CDR3 is typically longer
than in conventional VHs and can access concave or cryptic
epitopes not usually accessible by larger antibody fragments (De
Genst et al., 2006; Schmitz et al., 2013). An additional, desired
feature of sdAbs is that phage display and protein engineering are
technically straightforward compared to conventional antibodies
(Van Der Linden et al., 1999; Arbabi-Ghahroudi, 2017). SdAbs
are ideal modular units for genetic construction of multi-valent
or multi-specific formats (Els Conrath et al., 2001; De Bruin
et al., 2017; Nosenko et al., 2017; Li et al., 2018). Production
of sdAbs is also easier and more cost effective than full length
IgGs since sdAbs generally contain a single disulfide bond and
can be expressed to high yields in either the periplasm or cytosol
of microbial systems (Zarschler et al., 2013; Arbabi-Ghahroudi,
2017; Shriver-Lake et al., 2017; Liu and Huang, 2018; Suzuki
et al., 2018). These factors are important considerations in the
development and production of antibody treatments.
We previously identified a sdAb (AbiBodyTM) that binds
to the flagella of C. jejuni and reduces bacterial colonization
in chickens after sdAb treatment (Riazi et al., 2013). Here,
we present the characterization of a novel sdAb, termed Abi-
Se07, which targeted FliC, a flagellin protein of S. enterica.
In an attempt to identify a sdAb that inhibits Salmonella
invasion of host cells, FliC was chosen as a target. FliC is
a virulence factor and the most abundant molecule of the
flagella apparatus, forming the whip-like filament of the flagellum
responsible for motility of Salmonella (Chevance and Hughes,
2008; Evans et al., 2014). The flagellar apparatus of Salmonella
contributes to bacterial attachment to the host cell, facilitating
the invasion process (Elhadad et al., 2015; Salehi et al., 2017
and reviewed in Chaban et al., 2015). We show Abi-Se07
bound to bacterial cells of S. enterica serovar Hadar, Heidelberg,
Typhimurium, and directly to purified FliC of Typhimurium.
We also show that Abi-Se07 impeded the motility of S. enterica
serovar Hadar and Heidelberg. We demonstrate that treatment
with Abi-Se07 reduced bacterial growth in a human and avian
cell line. Importantly, S. enterica serovar Hadar growth was
inhibited upon treatment with Abi-Se07 in chicken jejunum





S. enterica serovars Typhimurium, Hadar, Heidelberg, Enteritidis,
Newport, Javiana, Senftenberg, Kentucky, Infantis, and Saint-
Paul each at a concentration of 1 × 109 CFU/mL in
adjuvant (aluminum hydroxide, 2% Alhydrogel) were used for
immunization of three male alpacas in a local farm (courtesy
of Dr. Maurice Smith) by subcutaneous injections of 0.4 mL.
Bacteria were cultured on Luria Broth (LB) agar plates, harvested
in phosphate buffered saline (PBS, BioShop) and inactivated by
heating at 65◦C for 30′. Injections were done on days 1, 15,
22, 29, and 36. Total RNA was isolated from lymphocytes using
RNAzol kit (Bioshop). Complementary DNA was synthesized
with oligo (dT) primers using the SuperScript III First Strand
cDNA synthesis kit (Invitrogen). Heavy chain variable regions
were PCR amplified using forward (5′) primers MJ1, MJ2, or
MJ3 and reverse primers (3′) CH2FORTA4 or CH2b3 (Arbabi-
Ghahroudi et al., 2009; Baral et al., 2013). A second PCR reaction
was conducted using the products of the first PCR reaction
with the forward and reverse primers MJ7 and MJ8, respectively
(Baral et al., 2013). These VHH PCR products were purified
with Cycle Pure Kit (Omega Bio-tek), digested with SfiI, and
re-purified using the same kit. Twelve micrograms of digested
DNA were ligated with 40 µg of Sfi-digested pADL-23c phagemid
vector (Antibody Design Labs) using T4 DNA ligase (Promega),
transformed into electrocompetent TG1 Escherichia coli cells
(Lucigen Corporation), and a library with a size of 7.8 × 108
transformants was obtained. Fifty clones were sequenced to
analyze diversity and all fifty contained unique CDR sequences
(Riazi et al., 2016). E. coli cells were infected with M13KO7
helper phage (New England Biolabs) in the presence of ampicillin
(100 ng/mL) and kanamycin (25 ng/mL) and the phage library
was precipitated in final concentration of 4% polyethylene glycol
8000 in 0.5 M NaCl and resuspended in PBS. Panning was
performed on 5 µg/mL of FliC (Sigma-Aldrich) coated on a 96-
well immunosorbent plate and blocked with 0.5% bovine serum
albumin (BSA) for 2 hrs. Approximately 2× 1012 phage particles
were added to BSA-only-coated wells for 1 h at 37◦C to select
out non-specific binders. The supernatant was then transferred
to FliC-coated wells and the plate was incubated for 2 h at 37◦C.
Wells were washed 5× with PBST (PBS, 0.1% Tween-20) and
bound phages eluted with 0.1 M triethylamine and neutralized
with 1M Tris-HCl, pH 7.4. Eluted phages were amplified by
infecting exponentially growing TG1 E. coli for 30′ at 37◦C
and then with helper phage for an additional 30′. Phages were
precipitated after 16 h incubation and used for the next round
of panning. Three additional panning rounds were conducted
following the same conditions except washing was increased 7, 10
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and, 12 times with phosphate-buffered saline with 0.1% Tween-
20 (PBST) for the second, third and fourth rounds, respectively.
After the fourth round, phage-infected TG1 cells were plated,
96 randomly picked colonies were grown for enzyme linked
immunosorbent assays (ELISAs) against FliC.
For clonal screening by ELISAs, 2.5 µg/mL of FliC was coated
on a 96-well immunosorbent plate and blocked with BSA. The
96 phage clones were then applied and the plate was incubated
for 1 h at room temperature (RT). After washing with PBST,
horse radish peroxidase (HRP)-conjugated anti-M13 monoclonal
antibody (GE Healthcare) at 1:5000 v/v concentration was
applied and the plate was incubated for 30′ at RT, shaking. Wells
were washed with PBST and 3, 3′, 5, 5′-Tetramethylbenzidine
(TMB) peroxidase substrate (Thermo Fisher) was added for
colorimetric quantification. Reactions were stopped with 1M
hydrochloric acid and absorbance was read at 450 nm using a
Cytation 5 plate reader (Biotek).
Cloning, Protein Expression and
Purification
The Abi-Se07 gene was synthesized (Integrated DNA
Technologies) and cloned into the pET27b bacterial expression
vector by Gibson assembly (Gibson et al., 2009). The sdAb
construct was expressed periplasmically in BL21 (DE3) E. coli
with a C-terminal c-myc tag followed by a His6-tag. Cells were
grown to mid-log phase in Terrific Broth (TB) media and induced
with 1 mM isopropylthio-β-galactoside (IPTG), extracted by
osmotic shock and purified by immobilized Nickel affinity
chromatography. Peak elutions were dialyzed into PBS and
quantified by UV spectrophotometry by absorbance at 280 nm.
Bacterial Binding by ELISAs
Heat-inactivated S. enterica serovar Hadar, Heidelberg
Typhimurium WT or flhD mutant EG11308 (Table 1) were
coated onto immunosorbant plates at 4◦C for 16 hrs. Plates
were blocked with 5% skim milk for 2 h at RT. SdAb constructs
were then applied at 250, 25, 2.5, 0.25, 0.025, and 0.0025 nM
for S. enterica and plates were incubated for 1 hr at RT. Plates
were then washed 6× with PBST (0.1% Tween-20) and HRP-
conjugated anti-His polyclonal antibody (Bethyl laboratories)
was applied at 1:5000 v/v concentration for 30′ at RT. Plates were
washed again 6× with PBST and TMB peroxidase substrate was
added for colorimetry quantification. Absorbance was read at
450 nm using Cytation 5.
TABLE 1 | Strains used in this study.










Park et al., 2015
S. enterica serovar Hadar Salmonella genetic stock
centre





Riazi et al., 2016
Salmonella Motility Assays
Exponentially growing S. enterica serovar Hadar or Heidelberg
were diluted to 0.01 OD600 and incubated with Abi-Se07 or anti-
Campylobacter irrelevant sdAb (for Heidelberg experiment) for
10′ at RT. One microliter of the mixture was spotted on Muller
Hinton-soft agar (1.5% MH media, 0.5% glucose, 0.5% agar) in
100 mm-diameter petri dishes and let dry for 10′. Plates were
incubated for 16–25 h at 37◦C in 5% CO2 (Forma Direct heat
incubator, Thermo Scientific) and imaged. Area of cell spread
was quantified using ImageJ software and analyzed using multiple
comparison ANOVA (Prism, GraphPad).
For dose-dependent motility assays, S. enterica was treated
with Abi-Se07 at varying concentrations for 10′ at RT and the
mixture was spotted on the corner of MH-soft agar pad at 0.3%
agar in a 96-well plate. After incubation for 16 hrs at 37◦C,
each well was applied with AlamarBlue (530–560 ex/590 em,
Thermo Fisher), which emits a red-fluorescent signal when it
becomes reduced by metabolically active cells. The plate was
incubated for 30′ at 37◦C, and fluorescence was read at the
center of each agar pad using Cytation 5 plate reader. Fully
motile cells would spread across the agar pad and exhibit higher
fluorescence signal at the center of the pad while non-motile
cells would remain at the corner of the pad and exhibit lower
signal (Rasmussen et al., 2011). Relative fluorescence units (RFU)
were plotted as a function of protein concentration and statistical




GFP-expressing S. enterica serovar Hadar or non-fluorescent
S. enterica serovar Hadar were treated with 500 µg/mL of Abi-
Se07 and incubated for 30′ at 37◦C. Then, confluent HeLa
cells (ATCC R© CCL-2TM) or QM7 cells (ATCC R© CRL-1962TM)
were infected at a multiplicity of infection (MOI) of 50 with
GFP expressing S. enterica serovar Hadar, or S. enterica serovar
Hadar, respectively. To quantify cell-associated Salmonella in
HeLa cells, fluorescence images were taken with Cytation 5
and fluorescent bacteria quantified. To measure intracellular
bacteria, HeLa or QM7 cells were then treated with 100 µg/mL
gentamicin and incubated for 1 h at 37◦C. Gentamicin is a non-
membrane permeable antibiotic and will kill non-internalized
bacteria. Finally, cells were washed 3× with PBS. For HeLa
cells, fluorescence images were taken with Cytation 5 and
fluorescent bacteria quantified. For QM7 cells, 0.1% saponin
solution was added and allowed to incubate with cells for 10′
at 37◦C. The mixture was then vortexed and homogenized for
cell lysis. Lysates were serially diluted and plated on LB agar for
CFU counting. Statistical analysis was performed using unpaired
student t-test.
Assaying Salmonella Invasion of Chicken
Intestinal Epithelium
For infection of chicken jejunum, intestinal sections (Lloyd
Weber Veterinary Clinic, Guelph, Ontario) were treated with
3× Hank’s Balanced Salt Solution (HBSS) and gentamicin at
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50 µg/mL final concentration. Sections were cut with 4 mm
diameter biopsy punches and placed into 24-well plate with
1 mL of Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal
bovine serum (FBS), and gentamicin. The plate was incubated at
37◦C for 1 h, then washed with HBSS at least 3×. S. enterica at
OD600 of 0.5 was treated with 500 µg/mL of Abi-Se07, incubated
at 37◦C for 20′, applied to the jejunum tissues, and the plate
was incubated for another hour. Tissues were then washed 2×
with HBSS and gentamicin was applied again for 15′. Tissues
were washed 3× with HBSS and incubated for 30′ in DMEM
and 10% FBS. Total DNA was extracted from the samples for
qPCR of the Salmonella ttr locus using the method described by
Malorny et al. (2004).
RESULTS
Identification of a Novel Anti-Salmonella
sdAb: Abi-Se07
Three male alpacas were subcutaneously immunized with 10
serovars of heat-inactivated cells of S. enterica to select for
antibodies with inter-serovar cross-reactivity. A phage-displayed
VHH library was generated from lymphocyte total RNA. We
performed panning/enrichment of the phage library against
FliC of serovar Typhimurium using ELISA. ELISAs and Sanger
sequencing were performed on 96 phage clones randomly chosen
after the last round of panning. We identified 18 unique
sequences, grouped based on CDR sequences that were specific
binders by ELISA (Table 2).
The clone 0A07 was selected based on neutralization of most
Salmonella strains tested. From here, it will be referred to as Abi-
Se07. It belongs to group 1 and contains a CDR3 20 amino acids
in length (Figure 1A), longer than the average CDR3 of sdAbs at
13–18 amino acids in length (Muyldermans et al., 1994; Vu et al.,
1997; Griffin et al., 2014). As a visualization exercise of Abi-Se07
TABLE 2 | Consensus amino acid sequences of CDR1, CDR2, and CDR3 of the
five groups of 18 anti-Salmonella VHHs.
CDR1
Group 1 GRX1FSX2KP 0A08; 1B08; 0A07; 1E05; 0H12;
1H07; 1E03; 0F09; 4D01; 0D12
Group 2 GLDFSSYA 4F10; 1E08; 3B04; 4F12
Group 3 GIIFSINA 2A09; 1G06
Group 4 GRSFSLYG 0A09
Group 5 GSIFSGDA 4C10
X1 = T or S; X2 = V or K
CDR2
Group 1 ASX3TGVST 0A08; 1B08; 0A07; 1E05; 0H12;
1H07; 1E03; 0F09; 4D01; 0D12
Group 2 ISRFGGRL 4F10; 1E08; 3B04; 4F12
Group 3 ISAYDHT 2A09; 1G06
Group 4 ISGSGLATS 0A09
Group 5 IGKEGDT 4C10
X3 = F or Y
CDR3
Group 1 AGTX4RTLWGSKWRDX5X6EYEY 0A08; 1B08; 0A07; 1E05; 0H12;
1H07; 1E03; 0F09; 4D01; 0D12
Group 2 AADRRSGLGTSKEYDY 4F10; 1E08; 3B04; 4F12
Group 3 NVDEIRKF 2A09; 1G06
Group 4 AQRWTSGTIARATGEYGY 0A09
Group 5 ATFEERPQPSYVY 4C10
X4 = T or L; X5 = V or R; X6 = L or R
binding to FliC, we modeled Abi-Se07, performed docking
simulations, and in silico alanine scanning (Supplementary
Figure S1 and Supplementary Table S1, respectively). The
CDR loops of the model are likely conformationally variable,
consistent with the lowered model quality around CDR regions,
lowest around CDR3 (Supplementary Figure S1C), indicating
FIGURE 1 | Anti-Salmonella Abi-Se07 sequence and purification. (A) Amino acid sequence of Abi-Se07 with CDR1-3 labeled according to IMGT numbering.
(B) Denaturing SDS-PAGE gel of Abi-Se07 after purification by IMAC.
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FIGURE 2 | Continued
FIGURE 2 | Abi-Se07 binds to S. enterica serovar Hadar, serovar
Typhimurium, and FliC protein. (A) Abi-Se07 (blue) and non-target
anti-Campylobacter irrelevant sdAb (red) were assayed for binding to whole
cells of S. enterica serovar Hadar (top panel) and Heidelberg (bottom panel)
by ELISA. Error bars represent standard deviation of three replicates.
(B) Abi-Se07 was assayed for binding to S. enterica serovar Typhimurium
(blue) and to the EG11308 fliD mutant of Typhimurium (red). EC50 values were
determined using non-linear regression one site binding model and indicated
with the standard error of the fit. Error bars represent standard deviation of
two independent replicates. (C) Sensorgrams of BLI experiments measuring
the binding of Abi-Se07 (top panel) and irrelevant sdAb (bottom panel) to FliC
flagellin of S. enterica serovar Typhimurium. SdAb was immobilized to
nickel-charged biosensors and dipped into different concentrations of FliC:
250, 125, 62.5, 31.3, and 15.6 nM (blue to orange). Dashed line separates
FliC association and FliC dissociation. KD value is indicated with standard
error of the fit.
the inaccuracy of the model. These in silico exercises merely
provide a to-scale visualization.
Abi-Se07 Binds to Cells of S. enterica
Serovar Heidelberg, Typhimurium, and
Hadar
Based on the docking results, we tested whether Abi-Se07
exhibited cross-serovar binding on three serovars, S. enterica
serovar Heidelberg, Typhimurium, and Hadar, of which the
latter two are globally prevalent in outbreaks (Lan et al., 2009;
Bogomolnaya et al., 2014). We expressed and purified Abi-Se07
(Figure 1B) and conducted ELISAs on whole cells of S. enterica
serovars Hadar, Heidelberg, and Typhimurium (Figures 2A,B).
Abi-Se07 exhibited binding to serovar Hadar and Heidelberg
while no binding was detected for the off-target control sdAb,
Irrelevant, which was developed to bind flagella of C. jejuni
(Hussack et al., 2014). Abi-Se07 also exhibited binding to serovar
Typhimurium and not to the flhD mutant (Park et al., 2015).
We determined, using biolayer interferometry (BLI), that Abi-
Se07 binds to purified FliC, with a KD of 16.2 ± 0.1 nM
(Figure 2C, upper panel), while the irrelevant sdAb did not
(lower panel). These results indicate that Abi-Se07 exhibits cross-
serovar binding, consistent with the docking simulations.
Bacterial Motility Is Inhibited With
Abi-Se07 Treatment
We next assessed Abi-Se07-dependent reduction of S. enterica
motility by preincubating bacteria with Abi-Se07 and plating the
mixture on soft agar (Figure 3). S. enterica serovar Typhimurium
was difficult to assay, exhibiting high degree of variability
in motility (Supplementary Figure S2). For this reason, we
focused on serovar Heidelberg and Hadar for our motility
studies. Treatment of these strains with Abi-Se07 resulted in
significant motility inhibition compared to non-target anti-
Campylobacter irrelevant sdAb (Figures 3A,B), BSA treatment
or buffer control (Figures 3C,D), suggesting that Abi-Se07 affects
bacterial motility by specifically binding FliC. To quantify the
magnitude of motility inhibition, dose-dependent motility assays
were conducted on S. Hadar (Figure 3E). Minimum inhibitory
concentration of motility (MICmot) was determined as the
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FIGURE 3 | Abi-Se07 inhibits the motility of S. enterica serovar Heidelberg and Hadar. (A) S. Heidelberg and (C) S. Hadar on soft agar plate. Four replicates are
shown. (B) Quantification of area of S. enterica serovar Heidelberg treated with Abi-Se07 or non-target anti_Campylobacter irrelevant sdAb. (D) Quantification of
area of S. Hadar treated with Abi-Se07, 75 µM BSA, or PBS buffer. Statistical significance between Abi-Se07 treatment and BSA or Buffer control is indicated by
p < 0.0005 using multiple comparisons ANOVA. Error bars represent standard deviation of the mean of four independent replicates. (E) Dose-dependent response
of Se07 on motility of S. Hadar. Minimum inhibitory concentration of motility (MICmot) is shown as dotted line with p = 0.0001 compared to Buffer treatment control.
Error bars represent standard deviation of four independent replicates.
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FIGURE 4 | Salmonella invasion of human and avian cell lines is reduced with Abi-Se07 treatment. (A) GFP-expressing S. enterica serovar Hadar treated with buffer
(left panel) or 500 µg/mL Abi-Se07 (right panel) were used to infect HeLa cells and imaged by fluorescence microscopy, pre-gentamicin. Fluorescent bacteria are
shown beside the white arrows. (B) Bar graph of fluorescent bacteria counts quantified from 7 different images. PBS treatment is in blue, Abi-Se07 treatment in red,
and no bacteria in green. (C) S. enterica serovar Hadar-infected HeLa cells were treated with gentamicin to remove extracellular bacteria to assess the number of
intracellular bacteria. Fluorescence microscopy images are shown for buffer treatment (left panel) and Abi-Se07 treatment (right panel). (D) Bar graph of fluorescent
bacteria counts, post-gentamicin, quantified from seven different images. PBS treatment is in blue, Abi-Se07 treatment in red, and no bacteria in green. Error bars
represent the standard deviation. Statistical significance was determined by unpaired student t-test. (E) Bar graph of mean CFU counts of intracellular S. enterica in
the presence and absence of Abi-Se07 treatment at 500 µg/mL. QM7 cells were infected with Abi-Se07-treated S. enterica (red) or buffer-treated S. enterica (blue)
and intracellular bacteria were quantified 1 h p.i. after gentamicin treatment. Error bars represent standard deviation of three independent replicates.
lowest concentration of sdAb (43.4 µM) that yielded significant
reduction in motility.
Bacterial Invasion of Eukaryotic Cells Is
Reduced After Treatment With Abi-Se07
S. enterica motility is essential for attachment and invasion
of eukaryotic cells (Elhadad et al., 2015; Salehi et al., 2017).
To evaluate the effect of Abi-Se07 on S. enterica infectivity,
attachment and invasion assays were performed using human
and avian cell lines. We co-incubated HeLa cells with
GFP-expressing S. enterica serovar Hadar treated with Abi-
Se07 and the number of adhered or intracellular bacteria
were quantified by fluorescence microscopy (Figures 4A,B).
A significant reduction of cell-associated bacteria were observed
in Abi-Se07-treated bacteria versus PBS-treated in both pre-
gentamicin (Figures 4A,B) and post-gentamicin experiments
(Figures 4C,D). Abi-Se07 treatment resulted in a 3-fold
reduction of bacteria in the pre-gentamicin experiment and a
2.5-fold reduction of internalized bacteria in the post-gentamicin
experiment. Next, the effect of Abi-Se07 on S. enterica infection
was assessed in the avian cell line, QM7, by quantifying
intracellular bacteria 1-h post-infection (1 h p.i.). Treatment
of S. enterica with Abi-Se07 resulted in 3.5-fold reduction
of internalized bacteria compared to control (Figure 4E).
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These results indicate that Abi-Se07 treatment of S. enterica
inhibits invasion of eukaryotic cells.
Abi-Se07 Dependent Reduction of
S. enterica Invasion of Chicken Gut
Tissue
To investigate the effect of Abi-Se07 using a relevant biological
sample, we performed invasion assays ex vivo with chicken
intestinal epithelium. Chicken jejunum sections were co-
incubated with Abi-Se07-treated S. enterica serovar Hadar. To
reduce non-specific signal from other bacteria present in the
tissue sections, the tetrathionate reductase (ttr) genetic locus
specific to Salmonella (Malorny et al., 2004) was used as a
reporter for quantitative PCR. The control treatment exhibited
3.5 × 109 ± 0.3 × 109 ttr DNA copies while the Abi-Se07
treatment showed 1.3 × 109 ± 0.1 × 109 DNA copies, a 2.7-fold
reduction (Figure 5). Taken together, Abi-Se07 has an inhibitory
effect on S. enterica invasion in natural host tissue.
DISCUSSION
An anti-Salmonella library of single domain antibodies was
created by immunizing alpacas with 10 different serovars of
S. enterica. FliC of serovar Typhimurium was chosen as this
serovar is one of the most commonly found serovars in both
humans and livestock (Lan et al., 2009; Bogomolnaya et al.,
2014). FliC was chosen as a target because it is an important
and abundant virulence factor of S. enterica and immunogenic
in humans (Alaniz et al., 2006).
We demonstrated that by panning with FliC, we could
extract a sdAb, Abi-Se07, with a KD of 16.2 nM, within
the mid-nM to high-pM range for sdAbs as reported by
others (Muyldermans and Lauwereys, 1999; Demeestere et al.,
2016; Sulea et al., 2018). Abi-Se07 contains a longer than
average CDR3 loop (Figure 1), and could suggest that its
CDR3 forms a convex paratope to access a cryptic epitope
on FliC as observed with other long CDR3 sdAbs (Stijlemans
et al., 2004; De Genst et al., 2006; Schmitz et al., 2013).
The accessibility of a cryptic epitope suggests that Abi-Se07
may target a conserved region on FliC, supported by the fact
that Abi-Se07 exhibited cross-serovar binding to whole cells of
S. enterica serovar Hadar, Heidelberg, and Typhimurium with
similar EC50 values. Binding of multiple antigen isoforms is a
desired property in therapeutic antibodies since the sdAb can
remain effective against highly mutagenic antigens. For example,
the sdAb was developed targeting the variant-specific surface
glycoprotein (VSG) of the parasite Trypanosome where a number
of different VSGs were effectively bound by the sdAb (Stijlemans
et al., 2004). Our docking simulations with Abi-Se07 model
identified a conserved region on FliC that may be accessible
by the sdAb with favorable binding energy (Supplementary
Figure S1B). However, these simulations remain to be validated
by empirical methods.
We demonstrated Abi-Se07 treatment reduced S. enterica
motility and invasion of different cell types. Motility assays
conducted with S. enterica serovars Hadar and Heidelberg were
FIGURE 5 | Salmonella invasion of chicken jejunum tissue is reduced with
Abi-Se07 treatment. Chicken jejunum sections were infected with
Abi-Se07-treated bacteria (at 500 µg/mL) and analyzed by qPCR of the ttr
genetic locus. Bar graph shows buffer treatment in blue and Abi-Se07
treatment in red. Error bars represent standard deviation of two replicates.
Statistical significance of ∗p = 0.0074 was calculated using unpaired student’s
t-test.
more consistent than with Typhimurium and could indicate
differences in environmental sensing, motility regulation, and
other virulence-related functions between the serovars (Suez
et al., 2013; Dhanani et al., 2015). Using S. enterica serovar
Hadar, we showed that bacterial invasion is significantly
reduced with Abi-Se07 treatment, which may still be due to
motility inhibition. This was observed on non-native host cells
(HeLa and QM7 cell lines) and native host tissue (jejunum
epithelium of chickens).
With KD in nanomolar range, it was unexpected that
MIC would be in micromolar range based on the proposed
mechanism of action and the Scatchard equation. We posit that
quantification error is minimal as two detection methods gave
consistent protein concentrations and aggregation of sdAb in
the assay conditions is unlikely as Tm ∼60◦C and antibodies
are relatively stable proteins. It is possible that this observation
is due to bacterial protease-associated inactivation of sdAbs.
Another alternative is that Abi-Se07 is binding flagella, disrupting
motility and resulting in reduced host cell invasion. Therefore,
the functional concentration of Abi-Se07 may be low due
to the abundance of the flagellar units and the small size
of the antibody.
A statistically significant reduction was observed upon Abi-
Se07 treatment on bacterial invasion in host cells, which may also
be due to inhibition of motility on mucus as a result of Abi-Se07
binding the flagella. Efforts are underway to further develop this
antibody into a therapeutic biologic and the results demonstrated
here pave the way for future sdAb development such as affinity
maturation by directed evolution, structure-guided engineering,
and synthetic library designs.
ANIMAL TISSUES
The broiler chicken intestinal tissue sections for our ex vivo
studies were obtained from chickens that had been already
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euthanized in a private practice: the Guelph Poultry Veterinary
Services under the guidance of Dr. Lloyd Weber, DVM, who
is affiliated with the Poultry Health Research Network of the
University of Guelph, and operates under the guidelines of the
University of Guelph Animal Care Committee.
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FIGURE S1 | (A) Alignment of S. enterica serovar Hadar (RAT91061.1),
Typhimurium (AHA06007.1), Heidelberg (AAT81640.1), Enteritidis (ERH38463.1),
Newport (APH26739.1), Javiana (OLP51747.1), Senftenberg (ABR18492.1).
Kentucky (KWV07712.1), Infantis (OSY33027.1), and Saint-Paul (KNU33033.1).
Domains D0, D1, D2, and D3 are colored black, gray, cyan, and green,
respectively. Underlined region corresponds to residues within 4 Å of Abi-Se07
CDRs in the simulated docking solution. (B) Visualization of docking of Abi-Se07
to FliC. This docking is inaccurate due to low quality modeling of CDRs (see C)
and is provided merely as a to-scale visualization. (C) SWISS-MODEL QMEAN
quality score relative to all non-redundant structures in the protein data bank
(left and right panels). Local quality estimate along the length of the sdAb
polypeptide (middle panel). Quality estimate declines around residue 100 to 120,
corresponding to CDR3.
FIGURE S2 | Motility of S. enterica was assessed for serovars Typhimurium and
Heidelberg. Three replicates were conducted for each set of experiments. In the
presence of BSA, PBS or irrelevant sdAb, Typhimurium exhibited inconsistent
motilities while Heidelberg exhibited consistent and reproducible motilities with the
control treatment.
TABLE S1 | Computational alanine scanning run with Robetta (www.bakerlab.org).
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